← Back to Conditions

Myositis

disorder
SNOMED 26889001CUI C0027121

Overview

By MedlinePlus, National Library of Medicine

NIH: National Institute of Neurological Disorders and Stroke Courtesy of the National Library of Medicine. Source: MedlinePlus.gov, National Library of Medicine. Not a substitute for medical advice.

Treatments & Interventions

Chlorzoxazone

substance

Cyclobenzaprine hydrochloride

substance

Chlorphenesin carbamate

substance

Metaxalone

substance

Tizanidine hydrochloride

substance

Orphenadrine

substance

Tizanidine

substance

Chlorphenesin

substance

Cyclobenzaprine

substance

Carisoprodol

substance

Orphenadrine citrate

substance

Methocarbamol

substance

Orphenadrine hydrochloride

substance

Signs & Symptoms

Based on Human Phenotype Ontology (HPO) disease-phenotype annotations.

Muscle inflammation
HP:0100614
Proximal neurogenic muscle weakness
HP:0003701

Related Conditions

Proliferative myositis(child)
Localised nodular myositis(child)
Maxillary myositis(child)
Infective myositis(child)
Polymyositis(child)
Interstitial myositis(child)
Inclusion body myositis(child)
Orbital myositis(child)
Lingual myositis(child)
Masticatory myositis(child)
Myositis in sarcoidosis(child)
Eosinophilic myositis(child)
Fibromyositis(child)
Talc granuloma of muscle(child)
Diaphragmitis(child)
Benign acute myositis(child)
Paraneoplastic myositis(child)
Autoimmune inflammation of skeletal muscle(child)
Dermatomyositis(child)
Idiopathic inflammatory myopathy(child)

Quick Facts

SNOMED CT
26889001
UMLS CUI
C0027121
Fully Specified Name
Myositis (disorder)
Specialists
0
Diagnostic Biomarkers
0
HPO Phenotypes
2
Known Treatments
13
Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Clinical content is derived from the SNOMED CT clinical ontology and curated medical knowledge graphs.